GenMark Diagnostics Inc (GNMK)

13.40
NASDAQ : Health Care
Prev Close 13.14
Day Low/High 13.05 / 13.62
52 Wk Low/High 4.73 / 13.62
Avg Volume 270.30K
Exchange NASDAQ
Shares Outstanding 47.05M
Market Cap 618.25M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GenMark Diagnostics Schedules Fourth Quarter 2016 Financial Results Conference Call For February 28, 2017

GenMark Diagnostics Schedules Fourth Quarter 2016 Financial Results Conference Call For February 28, 2017

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 28, 2017.

7 Stocks Making Big Moves With Unusual Volume

7 Stocks Making Big Moves With Unusual Volume

Here's a technical look at how to trade stocks rising with unusual volume flow.

Insiders Seeing Green With GNMK At New 52-Week High

Insiders Seeing Green With GNMK At New 52-Week High

In trading on Tuesday, shares of GenMark Diagnostics, Inc. touched a new 52-week high of $13.42/share.

This Small-Cap Rotation Is Unconvincing

This Small-Cap Rotation Is Unconvincing

Traders, pressed to find some action, are chasing certain things to a ridiculous extent.

GenMark Announces Preliminary Q4 2016 Financial Results

GenMark Announces Preliminary Q4 2016 Financial Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported preliminary fourth quarter 2016 revenue of $14.

GenMark Diagnostics To Present At The 2017 J.P. Morgan Healthcare Conference

GenMark Diagnostics To Present At The 2017 J.P. Morgan Healthcare Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 J.

Commit To Purchase GenMark Diagnostics At $10, Earn 17.6% Annualized Using Options

Commit To Purchase GenMark Diagnostics At $10, Earn 17.6% Annualized Using Options

Investors eyeing a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $12.23/share, might benefit from considering selling puts among the alternative strategies at their disposal.

GenMark Diagnostics Submits 510(k) Applications To The FDA For EPlex® Sample-to-Answer Instrument And Respiratory Pathogen Panel

GenMark Diagnostics Submits 510(k) Applications To The FDA For EPlex® Sample-to-Answer Instrument And Respiratory Pathogen Panel

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has submitted 510(k) applications to the FDA for its ePlex sample-to-answer...

GenMark Diagnostics Reports Q3 Financial Results

GenMark Diagnostics Reports Q3 Financial Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2016.

GenMark Diagnostics To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

GenMark Diagnostics To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the...

GenMark Diagnostics Schedules Third Quarter 2016 Financial Results Conference Call For November 3, 2016

GenMark Diagnostics Schedules Third Quarter 2016 Financial Results Conference Call For November 3, 2016

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016.

GenMark Diagnostics (GNMK) Stock Soars, Cowen Upgrades

GenMark Diagnostics (GNMK) Stock Soars, Cowen Upgrades

Cowen lifted GenMark Diagnostics (GNMK) stock rating to 'outperform,' citing positive reception of its ePlex device.

GenMark Diagnostics Reports Q2 Financial Results

GenMark Diagnostics Reports Q2 Financial Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.

GenMark Diagnostics To Present At The 36th Annual Canaccord Genuity Growth Conference

GenMark Diagnostics To Present At The 36th Annual Canaccord Genuity Growth Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th...

GenMark Diagnostics Schedules Second Quarter 2016 Financial Results Conference Call For July 28, 2016

GenMark Diagnostics Schedules Second Quarter 2016 Financial Results Conference Call For July 28, 2016

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, July 28, 2016.

GenMark Achieves CE Mark For Its EPlex® Sample-to-Answer System

GenMark Achieves CE Mark For Its EPlex® Sample-to-Answer System

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices...

Insider Trading Alert - GNMK, CLRO And ADSK Traded By Insiders

Insider Trading Alert - GNMK, CLRO And ADSK Traded By Insiders

Stocks with insider trader activity include GNMK, CLRO and ADSK

GenMark Diagnostics To Present At The William Blair 36th Annual Growth Stock Conference

GenMark Diagnostics To Present At The William Blair 36th Annual Growth Stock Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the...

Commit To Purchase GenMark Diagnostics At $7.50, Earn 31.2% Annualized Using Options

Commit To Purchase GenMark Diagnostics At $7.50, Earn 31.2% Annualized Using Options

Investors eyeing a purchase of GenMark Diagnostics, Inc. stock, but cautious about paying the going market price of $8.63/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Short Interest In GenMark Diagnostics Decreases By 11.2%

Short Interest In GenMark Diagnostics Decreases By 11.2%

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 558,337 share decrease in total short interest for GenMark Diagnostics, Inc. , to 4,404,251, a decrease of 11.25% since 04/15/2016.

Insider Trading Alert - PTC, EVR And GNMK Traded By Insiders

Insider Trading Alert - PTC, EVR And GNMK Traded By Insiders

Stocks with insider trader activity include PTC, EVR and GNMK

GenMark Reports First Quarter 2016 Results

GenMark Reports First Quarter 2016 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2016.

GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call For May 3, 2016

GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call For May 3, 2016

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 3, 2016.

Insider Trading Alert - GNMK, NEWT And ETM Traded By Insiders

Insider Trading Alert - GNMK, NEWT And ETM Traded By Insiders

Stocks with insider trader activity include GNMK, NEWT and ETM

Insider Trading Alert - GNMK, LKQ And USNA Traded By Insiders

Insider Trading Alert - GNMK, LKQ And USNA Traded By Insiders

Stocks with insider trader activity include GNMK, LKQ and USNA

Insider Trading Alert - GNMK, DIN And COR Traded By Insiders

Insider Trading Alert - GNMK, DIN And COR Traded By Insiders

Stocks with insider trader activity include GNMK, DIN and COR

GenMark Diagnostics Enters Oversold Territory (GNMK)

GenMark Diagnostics Enters Oversold Territory (GNMK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GenMark Reports Fourth Quarter And Full Year 2015 Results

GenMark Reports Fourth Quarter And Full Year 2015 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2015.